Due to the genetic linkage between SCN9A LOF mutations and CIP, developing specific inhibitors of NaV1.7 has become a major goal of pharmaceutical companies seeking to generate novel analgesics (Yekkirala et al., 2017). This evidence concerns the gene SCN9A and hereditary sensory and autonomic neuropathy.